linagliptin
Lilly and Boehringer diabetes drug sees US launch
March 24, 2015Sales and Marketing Boehringer, Glyxambi, Tradjenta, diabetes, empagliflozin/linagliptin, lilly, linagliptin
Lilly and Boehringer Ingelheim’s combo diabetes drug Glyxambi is now available to treat adult patients in the US. Glyxambi (empagliflozin/linagliptin) …
Boehringer and Lilly score FDA yes for Glyxambi
February 3, 2015Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin
The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …
Trajenta may reduce stroke damage
December 4, 2012Research and Development, Sales and Marketing Boehringer, EMA, Trajenta, diabetes, linagliptin
Boehringer Ingelheim’s diabetes drug Trajenta could one day be used to minimise the effects of brain damage following stroke. Scientists …
Lilly accused of anti-competitive practices
May 17, 2011Amylin, Boehringer, diabetes, exenatide, lilly, linagliptin
Amylin Pharmaceuticals is suing Eli Lilly and Company for alleged anticompetitive activity around Lilly’s January agreement with Boehringer Ingelheim to …
Lilly and Boehringer sign major diabetes collaboration
January 12, 2011Research and Development BI10773, Boehringer Ingelheim, Eli Lilly, LY2605541, LY2963016, TGF-beta monoclonal antibody, diabetes, lilly, linagliptin, type II diabetes
Eli Lilly and Boehringer Ingelheim have signed a multi-million dollar collaboration that will see them develop and commercialise a mid- …
Boehringer cheered by diabetes data
June 28, 2010Research and Development Boehringer, DPP-4, diabetes, linagliptin
Boehringer Ingelheim has been cheered by phase III data showing its new oral once-daily type II diabetes tablet linagliptin significantly …
